Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Pfizer and other ETFs, options, and stocks.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
88,000
Employees88,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
88,000
Employees88,000

PFE Key Statistics

Market cap
152.47B
Market cap152.47B
Price-Earnings ratio
35.74
Price-Earnings ratio35.74
Dividend yield
6.32%
Dividend yield6.32%
Average volume
41.47M
Average volume41.47M
High today
$27.25
High today$27.25
Low today
$26.56
Low today$26.56
Open price
$26.61
Open price$26.61
Volume
43.92M
Volume43.92M
52 Week high
$31.54
52 Week high$31.54
52 Week low
$24.48
52 Week low$24.48

PFE News

Benzinga 9h
Pfizer Antiviral Paxlovid's Extended Use Shows Mixed Results for Long COVID Relief: Study

A recent patient-led case series highlights the potential benefits of extended courses of Pfizer Inc's PFE Paxlovid (nirmatrelvir / ritonavir) for individuals w...

Pfizer Antiviral Paxlovid's Extended Use Shows Mixed Results for Long COVID Relief: Study
Investor's Business Daily 4d
Is Pfizer Stock A Buy After Rallying On Its 2025 Guidance?

Pfizer (PFE) stock has been working its way higher since mid-November and retook its 50-day line on the first trading day of 2025 after the company issued a mix...

Is Pfizer Stock A Buy After Rallying On Its 2025 Guidance?
Seeking Alpha 4d
Pfizer, Atavistik to collaborate on allosteric drug discovery

Pfizer (NYSE:PFE) has entered into a collaborative research agreement with Atavistik Bio for the discovery of novel precision allosteric therapeutics. The coll...

Pfizer, Atavistik to collaborate on allosteric drug discovery

Analyst ratings

50%

of 26 ratings
Buy
46.2%
Hold
50%
Sell
3.8%

More PFE News

The Motley Fool 4d
Got $5,000? These 3 Stocks Are Absurdly Cheap Buys Heading Into 2025

The stock market enjoyed a strong year in 2024 as the S&P 500 hit new records. The challenge for investors looking to get into the market amid such a strong bul...

Got $5,000? These 3 Stocks Are Absurdly Cheap Buys Heading Into 2025
TipRanks 5d
Drug Prices Are Increasing Again in 2025, But It’s Not as Bad as It Sounds

Drug prices are increasing today as many pharmaceutical companies bump up medication prices to help offset costs and provide funds for additional research. This...

TipRanks 6d
Sangamo selloff on Pfizer decision overdone, says H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio says that while Pfizer (PFE) ending its hemophilia A collaboration with Sangamo (SGMO) is disappointing, the 50% sellof...

Benzinga 6d
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

On Monday, Sangamo Therapeutics, Inc. SGMO regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy...

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
TipRanks 7d
Penny Stock Sangamo Nosedives as Pfizer Terminates Partnership

Shares of penny stock biotech company Sangamo Therapeutics (SGMO) dropped over 60% in Monday’s after-hours trading. The decline followed Pfizer’s (PFE) decision...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.